Jounce Therapeutics, Inc.
NASDAQ: JNCE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kimberlee Cobleigh Drapkin CPA
- Employees
- 141
- Headquarters
- Cambridge, United States
- IPO year
- 2017
- Market cap
- $99.0M
- Website
- https://jouncetx.com
Loading JNCE…
Loading profile data…Frequently asked questions about JNCE
What does Jounce Therapeutics, Inc. (JNCE) do?
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell...
Where does JNCE trade?
Jounce Therapeutics, Inc. (JNCE) trades on the NASDAQ Global Select.
What sector is JNCE in?
Jounce Therapeutics, Inc. (JNCE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Jounce Therapeutics, Inc.?
Kimberlee Cobleigh Drapkin CPA is the chief executive officer of Jounce Therapeutics, Inc. (JNCE).
Where is Jounce Therapeutics, Inc. headquartered?
Jounce Therapeutics, Inc. is headquartered in United States.
Does JNCE pay a dividend?
Jounce Therapeutics, Inc. (JNCE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did JNCE go public?
Jounce Therapeutics, Inc. (JNCE) completed its initial public offering in 2017.